Presentation of tumour antigens by dendritic cells and challenges faced
/in Dendritic Cells, International Publications /von 2010-01-29 / Curr. Opin. Immunol. 2010 Feb;22(1):137-44Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus
/in International Publications, Newcastle Disease Virus /von 2010-01-25 / Oncogene 2010 Apr;29(15):2205-16Tocotrienols are good adjuvants for developing cancer vaccines
/in Dendritic Cells, International Publications /von 2010-01-06 / BMC Cancer 2010 Jan;10:5The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2010-01-01 / J. Virol. 2010 Jan;84(1):639-46Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study
/in Hyperthermia, International Publications, Ovarian Cancer /von 2010-01-01 / Int J Hyperthermia 2010;26(2):118-26Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data
/in Breast Cancer, Hyperthermia, International Publications /von 2010-01-01 / Int J Hyperthermia 2010;26(7):612-7Heat shock proteins in glioblastomas
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications /von 2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):111-23Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2010-01-01 / Neoplasma 2010;57(5):455-64Biological rationales and clinical applications of temperature controlled hyperthermia–implications for multimodal cancer treatments
/in Hyperthermia, International Publications /von 2010-01-01 / Curr. Med. Chem. 2010;17(27):3045-57
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution